FSSAI launches dedicated licensing window for Ayurveda Aahara products

New Delhi:  The Food Safety and Standards Authority of India (FSSAI), under the Ministry of Health and Family Welfare, has officially launched a dedicated licensing and registration window for Ayurveda Aahara products on its Food Safety Compliance System (FoSCoS) portal. This significant step will enable manufacturers across India to seamlessly apply for licenses to produce and market traditional Ayurvedic foods.

The new ‘Kind of Business’ (KoB) framework for Ayurveda Aahara aims to formalise and streamline the sector, aligning traditional recipes—as documented in authoritative Ayurveda texts—with contemporary food safety and quality standards. This move is designed to boost the food and Ayurveda industries by creating a regulated pathway for these products to reach the market.

This regulation is rooted in the core Ayurvedic principle of personalized nutrition, which tailors diet to an individual’s specific constitution (prakriti). By standardizing these traditional formulations, the FSSAI measure is expected to support the growth of the food and Ayurveda industries. Furthermore, the availability of authentic and regulated Ayurveda Aahara will serve as a critical support for prescribed Ayurvedic treatment plans.

To facilitate a smooth transition for the industry, FSSAI has already published a list of 91 approved Ayurveda Aahara recipes via an order dated 25th July 2025. This provides Food Business Operators with a clear, pre-approved reference for manufacturing products under this new category, ensuring both authenticity and regulatory compliance.

This initiative, developed in close collaboration with the Ministry of Ayush, reflects the Government of India’s commitment to integrating the profound wisdom of Ayurveda with modern food safety practices, thereby benefiting both industry stakeholders and public health.

Related Posts

HP HC quashes CDSCO complaints against pharma firms over jurisdictional and procedural lapses

In a landmark ruling that will have far-reaching implications for the pharmaceutical sector, the High Court of Himachal Pradesh has quashed three criminal complaints filed by the Central Drugs Standard…

Eli Lilly launches cancer drug Tanstrive in India

New Delhi: Eli Lilly and Company India on Thursday announced the launch of its cancer treatment drug Tanstrive in India. The launch follows marketing authorisation from the Central Drugs Standard Control Organisation…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

HP HC quashes CDSCO complaints against pharma firms over jurisdictional and procedural lapses

HP HC quashes CDSCO complaints against pharma firms over jurisdictional and procedural lapses

Eli Lilly launches cancer drug Tanstrive in India

Eli Lilly launches cancer drug Tanstrive in India

Sir Ganga Ram Hospital excels in Medical Research among Private Hospitals

Sir Ganga Ram Hospital excels in Medical Research among Private Hospitals

Centre eases BIS quality compliance with new risk-based framework for manufacturers

Centre eases BIS quality compliance with new risk-based framework for manufacturers

SS Innovations International aces Race beating Global Giants in Surgical Robotics

SS Innovations International aces Race beating Global Giants in Surgical Robotics

‘SHE’ comes all the Way from Calcutta to Delhi to Care for Women’s Fertility

‘SHE’ comes all the Way from Calcutta to Delhi to Care for Women’s Fertility